PARP3 Inhibitors
2 drugsAbout PARP3
PARP3, or poly(ADP-ribose) polymerase 3, is a protein involved in DNA repair and other cellular processes. While its exact function is still being researched, its role in DNA damage response makes it a potential target for cancer therapy.
Inhibiting PARP3 activity could disrupt DNA repair mechanisms in cancer cells, making them more susceptible to cell death. Currently, there is no genetic evidence data available linking PARP3 directly to specific diseases.
There is one FDA-approved drug, LYNPARZA (AstraZeneca), that targets PARP proteins and has 4 indications in oncology. LYNPARZA is a small molecule and was first approved in 2014.
Top PARP3 Drugs
AstraZeneca is the only company with an approved drug targeting PARP3.
High market concentration suggests significant entry barriers; consider strategic partnerships.
PARP3 Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets PARP3, using small molecule modality.
Explore alternative modalities like antibodies or PROTACs to differentiate from existing PARP inhibitors.
PARP3 Clinical Trials 401 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on PARP3. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 140 | 60 | 24 | 56 | 71% |
| Phase 2 | 208 | 64 | 36 | 108 | 64% |
| Phase 3 | 47 | 20 | 2 | 25 | 91% |
| Phase 4 | 6 | 2 | 0 | 4 | 100% |
Top Sponsors
By Modality
Top Conditions
Phase 3 Readout Calendar Pro
2 Phase 3 trials testing approved PARP3 drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting PARP3. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
PARP3 Drug Approval Timeline (2016 - 2016)
LYNPARZA was first approved in 2014 and remains the most recent approval.
The approval timeline indicates potential saturation; focus on novel indications or combination therapies.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 170 (33 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on PARP3. A trial counts if an approved drug acting on PARP3 is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.